Cover Image
市場調查報告書

脂蛋白元A-I (ApoA-I):開發中產品分析

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 364851
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
脂蛋白元A-I (ApoA-I):開發中產品分析 Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 57 Pages
簡介

本報告提供以脂蛋白元A-I (ApoA-I)為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

脂蛋白元A-I (ApoA-I) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Advaxis, Inc.
  • Akshaya Bio Inc.
  • Celgene Corporation
  • Etubics Corporation
  • OSE Immunotherapeutics
  • Vaxon Biotech

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0596TDB

Summary

Global Markets Direct's, 'Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016', provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein A I (APOA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A I (APOA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Apolipoprotein A I (APOA1)
  • The report reviews Apolipoprotein A I (APOA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Apolipoprotein A I (APOA1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Apolipoprotein A I (APOA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Apolipoprotein A I (APOA1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Apolipoprotein A I (APOA1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Apolipoprotein A I (APOA1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Apolipoprotein A I (APOA1) Overview
  • Therapeutics Development
    • Apolipoprotein A I (APOA1) - Products under Development by Stage of Development
    • Apolipoprotein A I (APOA1) - Products under Development by Therapy Area
    • Apolipoprotein A I (APOA1) - Products under Development by Indication
  • Apolipoprotein A I (APOA1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Apolipoprotein A I (APOA1) - Products under Development by Companies
  • Apolipoprotein A I (APOA1) - Products under Development by Universities/Institutes
  • Apolipoprotein A I (APOA1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Apolipoprotein A I (APOA1) - Companies Involved in Therapeutics Development
    • Arisaph Pharmaceuticals, Inc.
    • Cerenis Therapeutics Holding SA
    • CSL Limited
    • Esperion Therapeutics, Inc.
    • KineMed, Inc.
  • Apolipoprotein A I (APOA1) - Drug Profiles
    • 4-WF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARI-1778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CER-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CER-522 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-4F - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Apolipoprotein A I (APOA1) - Dormant Projects
  • Apolipoprotein A I (APOA1) - Discontinued Products
    • Apolipoprotein A I (APOA1) - Featured News & Press Releases
      • Sep 01, 2016: Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology Congress 2016
      • Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule
      • Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS)
      • Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
      • Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015
      • Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients
      • Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study
      • Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated
      • Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
      • Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies
      • Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS
      • Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001
      • Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development
      • Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
      • Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Pipeline by CSL Limited, H2 2016
  • Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Pipeline by KineMed, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top